ストックスクリーナーアプリを入手
42.57
13.89%
5.1847
前日終値:
$37.39
開ける：
$39.375
24時間の取引高:
1.44M
Relative Volume:
1.27
時価総額：
$2.55B
収益：
$66.05M
当期純損益:
$-422.60M
株価収益率:
-5.8716
EPS:
-7.251
ネットキャッシュフロー:
$-384.73M
1週間 パフォーマンス:
+14.75%
1か月 パフォーマンス:
+50.53%
6か月 パフォーマンス:
+49.21%
1年 パフォーマンス:
+20.95%
1日の値動き範囲:
$39.38
$42.95
1週間の範囲:
$36.35
$42.95
52週間の値動き範囲:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
42.83 | 2.23B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
524.21 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
668.24 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.94 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.13 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.01 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-20 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 開始されました | Piper Sandler | Overweight |
| 2022-11-17 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-02-15 | 繰り返されました | Needham | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-08-10 | 繰り返されました | Needham | Buy |
| 2017-08-08 | 繰り返されました | SunTrust | Buy |
| 2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | ダウングレード | Janney | Buy → Neutral |
| 2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 開始されました | Needham | Buy |
| 2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $42.62, Implies 14% Upside - TradingView
AGIO Maintained by B of A Securities -- Price Target Raised to $46 - GuruFocus
Agios Pharmaceuticals (AGIO) Gains FDA Priority Review for Pyruk - GuruFocus
Agios Pharmaceuticals (AGIO) Receives FDA Priority Review for Mi - GuruFocus
RBC Capital Adjusts Agios Pharmaceuticals PT to $32 From $28, Maintains Sector Perform Rating - marketscreener.com
Agios gains FDA priority review for Pyrukynd label expansion - Seeking Alpha
Agios Says US FDA Grants Priority Review for Mitapivat to Treat Sickle Cell Disease - marketscreener.com
FDA accepts Agios sNDA for mitapivat in sickle cell disease By Investing.com - Investing.com Canada
FDA puts Agios' sickle cell drug on fast track to Nov. 1 review date - Stock Titan
Price to sales forward of Agios Pharmaceuticals, Inc. – MUN:8AP - TradingView
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Price to book forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
AGIOAgios Pharmaceuticals Inc Latest SEC Filings - Finviz
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock - Investing.com
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com - Investing.com India
D. E. Shaw reports 3.03M-share stake in Agios (AGIO) - Stock Titan
Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale - Stock Titan
AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker - Stock Titan
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) dropped from Russell 2000 Defensive Index - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2500 Growth Benchmark - marketscreener.com
Agios Pharmaceuticals to announce Q2 2026 results on July 30 - scanx.trade
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET - The Manila Times
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at ... - Caledonian Record
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 A.m. ET - Moomoo
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 3000 Growth Benchmark - marketscreener.com
Agios Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AGIO) - TradingView
Agios Pharmaceuticals Insider Lowered Holding By 91% During Last Year - Moomoo
Agios Pharmaceuticals, Inc. Actuals & Estimates (DUS:8AP) - TradingView
Agios Pharmaceuticals, Inc. Actuals & Estimates (MUN:8AP) - TradingView
AGIO stock surges 35% in six months: What's driving it? - MSN
AGIO Forecast — Price Target — Prediction for 2027 - TradingView
0HB0 Forecast — Price Target — Prediction for 2027 - TradingView
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) - AOL.com
Precision Trading with Agios Pharmaceuticals Inc. (AGIO) Risk Zones - Stock Traders Daily
Agios to discontinue candidate for myelodysplastic syndromes - MSN
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54 - Moomoo
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed? - Sahm
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $36 - Moomoo
Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives new stock options and RSU awards - Stock Titan
Agios Pharmaceuticals (AGIO) director reports new equity awards and RSU vesting - Stock Titan
Agios (NASDAQ: AGIO) director receives new options and RSU awards - Stock Titan
AGIOS (AGIO) director Maykin Ho exercises RSUs and receives new equity awards - Stock Titan
Agios (NASDAQ: AGIO) director receives stock options, RSUs and exercises units - Stock Titan
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Owen Adams Catherine - Moomoo
Agios Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Scadden David - Moomoo
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Sale |
37.56 |
4,007 |
150,503 |
84,645 |
1.16%
0.48%
大文字化:
|
ボリューム (24 時間):